Articles
🌏 Asia-PacificExpert insights, opinion pieces, and in-depth analysis on pharmaceutical trends and NMPA regulations.
Reckitt Benckiser Layoffs Hit NJ: Mucinex Maker Cuts Jobs
Reckitt Benckiser, the company behind Mucinex, has announced further layoffs in New Jersey. This move signals ongoing restructuring within the pharmaceutical giant and reflects broader industry trends.
Reckitt Benckiser Layoffs: Mucinex Maker Cuts Jobs in NJ
Reckitt Benckiser, the company behind Mucinex, has announced further layoffs in New Jersey. This move signals ongoing strategic adjustments within the pharmaceutical giant.
Auvelity FDA Approval: New MDD Treatment Option
The FDA has approved Auvelity, a new oral antidepressant from Axsome Therapeutics, offering a novel mechanism of action for adults with major depressive disorder (MDD). This landmark approval signifies a significant advancement in depression treatment options.
NMPA Clinical Trial Regulations: Impact on Multinational Pharma Data & Inspections
This article delves into the NMPA clinical trial regulations and their significant impact on multinational pharmaceutical data management and inspection processes.
SAKIGAKE Designation Japan: Bispecific Antibodies for Leukemia Status 2026
This article delves into the SAKIGAKE Designation in Japan for bispecific antibodies, focusing on their potential to transform leukemia treatment by 2026.
PMDA Guideline Updates: Impact on Adaptive Trial Designs & Data Transparency
This article delves into the recent PMDA guideline updates and their implications for adaptive trial designs and data transparency in drug development.
Harmonization of Clinical Trial Regulations: PMDA, TGA & CDSCO Compared
This article compares the clinical trial regulations of PMDA, TGA, and CDSCO, focusing on their impact on drug development and patient safety.
NMPA Conditional Approval: What You Need to Know About China's Expedited Drug Pathway
Learn about China's NMPA Conditional Approval process, designed to expedite access to critical medications like XYZ for cancer patients.
Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Era
Purdue Pharma, the manufacturer of OxyContin, is ceasing operations as part of a $7.4 billion settlement to resolve claims related to the opioid crisis. This landmark deal signifies a major turning point in the legal and societal reckoning with the epidemic.
NMPA Accelerated Approval Pathway: Impact on Innovative Drug Market Entry in China
The NMPA Accelerated Approval Pathway significantly enhances the speed of innovative drug market entry in China, particularly for critical cancer treatments.
NMPA Approval Lung Cancer Immunotherapy: PD-1/PD-L1 Combo Trends 2025
This article delves into the NMPA's approval landscape for lung cancer immunotherapy, highlighting the emerging trends of PD-1/PD-L1 combination therapies by 2025.
NMPA Conditional Approval Pathway: Impact on Innovative Oncology Drug Access
The NMPA Conditional Approval Pathway significantly enhances access to innovative oncology drugs, facilitating timely treatment options for cancer patients.
African Medicines Agency Implementation: Transforming Regulatory Harmonization & Market Access
The African Medicines Agency is set to revolutionize regulatory processes, ensuring faster market access for vital medicines across the continent.
NMPA Priority Review Pathway: Accelerating Innovative Drug Approvals in China
The NMPA Priority Review Pathway accelerates the approval of innovative drugs in China, significantly benefiting patients with critical health needs.
PMDA SAKIGAKE Designation: Accelerating Innovative Therapies in Japan
The PMDA SAKIGAKE Designation fast-tracks innovative therapies, such as XYZ Drug for cancer, enhancing patient access to groundbreaking treatments in Japan.
PMDA SAKIGAKE Designation: Accelerating Innovation in Japan's Pharma Sector
The PMDA SAKIGAKE Designation is transforming Japan's pharmaceutical landscape, expediting the development of innovative drugs like XYZ for cancer treatment.
NMPA Data Integrity Requirements: What Foreign Pharma Must Know in APAC
Understanding NMPA data integrity requirements is essential for foreign pharmaceutical companies aiming to navigate drug registration in the APAC region.
Clinical Trial Quality Management Systems: New APAC Standards & Challenges
This article delves into the latest APAC standards for clinical trial quality management systems, highlighting challenges in ensuring drug efficacy and patient safety.
Clinical Trial Regulatory Harmonization: NMPA & PMDA ICH Adoption in APAC
This article delves into the regulatory harmonization of clinical trials in APAC, focusing on NMPA and PMDA's ICH adoption to expedite drug approvals.
Biosimilar Market in Japan: Growth Trends Post-PMDA Guideline Revisions
The biosimilar market in Japan is experiencing significant growth following PMDA guideline revisions, impacting drugs such as adalimumab for rheumatoid arthritis.